Stephen Poor

Company: Novartis AG

Job title: Executive Director & Head of Global Program Clinical

Seminars:

Panel Discussion: Maximizing Ophthalmic Gene Therapy Trial Success Strategies 9:30 am

Discussing strategies for improving trial design to mitigate risks and enhance success Exploring the regulatory landscape and its impact on gene therapy trials, including approval processes and compliance requirements Detailing actionable steps derived from past failures to inform future gene therapy endeavours and maximize trial outcomesRead more

day: Day Two 12th

Extracting Insights from Novartis for Future Gene Therapy Development 9:00 am

Analyzing factors contributing to failures in gene therapy development for ophthalmic disorders Highlighting pitfalls and challenges encountered in clinical trials and translational research Presenting case studies of failed gene therapy programs and the key lessons learned from these setbacksRead more

day: Day Two 12th

Optimizing Endpoint Selection in Ophthalmic Gene Therapy Trials 9:00 am

Choosing appropriate endpoints is pivotal for accurately evaluating the efficacy of ophthalmic gene therapy. This workshop provides a cohesive exploration of innovative strategies to enhance endpoint selection, ensuring validity, reliability, and patient-centricity in ocular gene therapy trials. Key Discussion Points: Advancing Visual Function Assessment: Exploring advancements in visual function assessment methodologies tailored for gene therapy…Read more

day: Pre-Conference Workshop Day Clinical Track AM